Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR.

J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.

2.

Goserelin acetate in combination with radiotherapy for prostate cancer.

Roach M 3rd, Izaguirre A.

Expert Opin Pharmacother. 2007 Feb;8(2):257-64. Review.

PMID:
17257094
3.
4.

Locally advanced prostate cancer: effective treatments, but many adverse effects.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):18-20, 22-3. Review.

PMID:
23367679
5.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
7.

Endocrine treatment of prostate cancer.

Tammela T.

J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. Epub 2004 Dec 31. Review.

PMID:
15663992
8.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
9.

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS.

Cancer. 2005 Apr 15;103(8):1615-24. Review.

10.

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.

Basaria S.

J Androl. 2008 Sep-Oct;29(5):534-9. doi: 10.2164/jandrol.108.005454. Epub 2008 Jun 20. Review.

11.
12.

Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer.

Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T.

Prostate Cancer Prostatic Dis. 2008;11(1):46-52. Epub 2007 Jul 3. Review.

PMID:
17607304
13.

Contemporary role of androgen deprivation therapy for prostate cancer.

Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, Studer UE.

Eur Urol. 2012 Jan;61(1):11-25. doi: 10.1016/j.eururo.2011.08.026. Epub 2011 Aug 19. Review.

14.

Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.

Taylor LG, Canfield SE, Du XL.

Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. Review.

15.

Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.

Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1293-301. doi: 10.1016/j.ijrobp.2010.07.2004. Epub 2011 Mar 31. Review.

16.

[Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].

Tschöpe C, Kherad B, Spillmann F, Schneider CA, Pieske B, Krackhardt F.

Herz. 2016 Apr 15. [Epub ahead of print] Review. German.

PMID:
27083586
Items per page

Supplemental Content

Write to the Help Desk